A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity

T cell–engaging bispecific antibodies (TCB) are highly potent therapeutics that can recruit and activate cytotoxic T cells to stimulate an antitumor immune response. However, the development of TCBs against solid tumors has been limited by significant on-target toxicity to normal tissues. Probody th...

Descripción completa

Detalles Bibliográficos
Autores principales: Boustany, Leila M., LaPorte, Sherry L., Wong, Laurie, White, Clayton, Vinod, Veena, Shen, Joel, Yu, Wendy, Koditek, David, Winter, Michael B., Moore, Stephen J., Mei, Li, Diep, Linnea, Huang, Yuanhui, Liu, Shouchun, Vasiljeva, Olga, West, Jim, Richardson, Jennifer, Irving, Bryan, Belvin, Marcia, Kavanaugh, W. Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664135/
https://www.ncbi.nlm.nih.gov/pubmed/36112781
http://dx.doi.org/10.1158/0008-5472.CAN-21-2483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664135/
https://www.ncbi.nlm.nih.gov/pubmed/36112781
http://dx.doi.org/10.1158/0008-5472.CAN-21-2483

Ejemplares similares